Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Compound screening

Using state-of-the-art equipment and the newly developed iPSC stem cell resource, scientists are investigating the behaviour of industry-developed drugs in new contexts.

© Anna Lukala
Universities are now able to carry out compound screening on a scale which facilitates collaboration with industry

The Wade-Martins group (University of Oxford) have set up successful collaborative projects with industry. This has enabled screening of large compound libraries using complex ‘disease in a dish’ models for various neurodegenerative diseases derived from reprogrammed iPSCs.

 

Richard Wade-Martins' group at the University of Oxford

For more information contact richard.wade-martins@dpag.ox.ac.uk, brent.ryan@dpag.ox.ac.uk or deepak.kumar@dpag.ox.ac.uk.

Research in action

Scientists are uncovering the potential on the shelves of the drug libraries.

Learn more

The research team